Skip to main content
Premium Trial:

Request an Annual Quote

Oxford GlycoSciences CEO Kranda to Step Down

NEW YORK, March 7 - Oxford GlycoSciences on Thursday said that CEO Michael Kranda will step down by the end of this year.

The company said Kranda, who has been at OGS for six years, cited "personal family reasons" for his decision to leave. Chairman G. Kirk Raab said the company has begun looking for a replacement.

 

Kranda "will stay on through the transition period and I am confident that OGS' programmes and progress will continue unabated," Raab said in a statement.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.